Meeting
2023 ASCO Annual Meeting
Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.
Authors
Christophe Le Tourneau
Institut Curie, Paris, France
Christophe Le Tourneau , Frederic Rolland , Olivier Capitain , Amaury Daste , Philippe Alexandre Cassier , Sebastien Salas , Luis Manso Sánchez , Antonio Casado Herraez , Gerardo Colon-Otero , Lauriane Eberst , Camille Jamet , Ana Lalanne , Olivier Lantz , Hakim Makhloufi , Annette TAVERNARO , Kaidre Bendjama , Maud Brandely-Talbot , Jean-Pierre Delord
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
03260023
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2630)
DOI
10.1200/JCO.2023.41.16_suppl.2630
Abstract #
2630
Poster Bd #
472
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer.
First Author: Amishi Yogesh Shah
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma.
First Author: Ritesh Kotecha
Poster
2021 ASCO Annual Meeting
Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
First Author: Alain Patrick Algazi
Poster
2020 ASCO Virtual Scientific Program
OSTPDL1: A phase II study of avelumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1) in adolescent and young adult patients with recurrent or progressive osteosarcoma.
First Author: Michael William Bishop